Home » Topics » HIV/AIDS, BioWorld Science

HIV/AIDS, BioWorld Science
RSS

Orion's OB-002 shown to be more potent than maraviroc in a model of HIV infection

July 25, 2019

Preliminary phase I data for the long-acting HIV capsid inhibitor GS-6207

July 25, 2019

Merck & Co. presents clinical data for MK-8591 in patients with HIV-1 infection

July 25, 2019

Gilead presents data on TLR7 agonists vesatolimod and GS-986

July 24, 2019

Dolutegravir recommended by WHO for first-line and second-line treatment for HIV

July 23, 2019

New assays mean new insights into HIV reservoir

July 23, 2019

At HIV Science meeting, lively discussion on what a cure will take

July 22, 2019

New public-private partnership to support phase III trial of Janssen's mosaic-based HIV vaccine

July 16, 2019

Merck & Co., Idenix Pharmaceuticals describe HIV-1 reverse transcriptase/ribonuclease H inhibitors

July 8, 2019

GlaxoSmithKline identifies new IDO1 inhibitors for HIV infection

July 4, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...